A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study
J Proietto, A Rissanen, JB Harp, N Erondu, Q Yu, S Suryawanshi, ME Jones, AO Johnson-Levonas, SB Heymsfield, KD Kaufman, JM Amatruda
International Journal of Obesity | NATURE PUBLISHING GROUP | Published : 2010
The study was funded by Merck & Co. The authors JBH, NE, QY, SS, MEJ, AOJ-L, SBH, KDK and JMA are employees of Merck & Co. Inc., and may hold stock in that company. JP is a member of a Merck Diabetes and Obesity Global Expert Committee.